⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MLTX News
MoonLake Immunotherapeutics Class A Ordinary Shares
Form 8-K
sec.gov
MLTX
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
globenewswire.com
MLTX
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
globenewswire.com
IMA
MLTX
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
globenewswire.com
MLTX
Morning Market Pulse: From Orbit to Biomaterials, Innovation Drives the Tape
globenewswire.com
FLYX
ACON
MLTX
MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day
globenewswire.com
MLTX
Join Class Action to Recover Losses from MoonLake Immunotherapeutics (MLTX) - Contact Levi & Korsinsky Before December 15, 2025
accessnewswire.com
MLTX
Pomerantz LLP Reminds Shareholders with Losses on their Investment in MoonLake Immunotherapeutics – MLTX
accessnewswire.com
MLTX
Contact Levi & Korsinsky by December 15, 2025 Deadline to Join Class Action Against MoonLake Immunotherapeutics(MLTX)
globenewswire.com
MLTX
MLTX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important December 15 Deadline in Securities Class Action - MLTX
accessnewswire.com
MLTX